Published in J Immunol on May 01, 2004
High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS One (2007) 1.25
Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope. J Immunol (2007) 1.01
Primary human immunodeficiency virus type 1-specific CD8+ T-cell responses induced by myeloid dendritic cells. J Virol (2009) 0.95
Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. Eur J Immunol (2010) 0.88
Multiple T-cell responses to human immunodeficiency virus type 1 are enhanced by dendritic cells. Clin Vaccine Immunol (2009) 0.87
HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor. J Transl Med (2009) 0.86
Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol (2009) 0.82
CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection. J Acquir Immune Defic Syndr (2011) 0.82
Induction of primary anti-HIV CD4 and CD8 T cell responses by dendritic cells transduced with self-inactivating lentiviral vectors. Cell Immunol (2006) 0.81
The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses. PLoS One (2013) 0.80
Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer. Arch Immunol Ther Exp (Warsz) (2008) 0.76
Schistosoma mansoni soluble egg antigens enhance T cell responses to a newly identified HIV-1 Gag H-2b epitope. Clin Vaccine Immunol (2014) 0.75
Structure-based prediction of protein-protein interactions on a genome-wide scale. Nature (2012) 3.37
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest (2002) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis. Cancer Res (2004) 1.29
Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One (2008) 1.20
Arginine methylation of RNA helicase a determines its subcellular localization. J Biol Chem (2004) 1.19
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis (2012) 1.13
Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells. J Biol Chem (2001) 1.13
RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator. Eur J Biochem (2004) 1.13
Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus. Nucleic Acids Res (2004) 1.10
TGF-β is responsible for NK cell immaturity during ontogeny and increased susceptibility to infection during mouse infancy. Nat Immunol (2012) 1.08
Degeneracy and repertoire of the human HIV-1 Gag p17(77-85) CTL response. J Immunol (2006) 1.08
Identification of cellular cofactors for human immunodeficiency virus replication via a ribozyme-based genomics approach. J Virol (2004) 1.08
A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology (2012) 1.06
Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol (2010) 1.06
One-week 96-well soft agar growth assay for cancer target validation. Biotechniques (2004) 1.04
Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis (2013) 0.99
RNA interference and potential applications. Curr Top Med Chem (2006) 0.94
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology (2014) 0.93
A more efficient RNAi inducible system for tight regulation of gene expression in mammalian cells and xenograft animals. RNA (2007) 0.92
Functional interaction of Sam68 and heterogeneous nuclear ribonucleoprotein K. Oncogene (2002) 0.92
Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res (2008) 0.92
Increased extracellular pressure enhances cancer cell integrin-binding affinity through phosphorylation of beta1-integrin at threonine 788/789. Am J Physiol Cell Physiol (2008) 0.91
Transduction of cell lines and primary cells by FIV-packaged HIV vectors. Mol Ther (2004) 0.88
Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor. Bioorg Med Chem Lett (2012) 0.88
Orphan G protein-coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway. Mol Cancer Ther (2007) 0.88
Biochemical characterization of genetic mutations of GPR56 in patients with bilateral frontoparietal polymicrogyria (BFPP). Biochem Biophys Res Commun (2007) 0.88
A role for KH domain proteins (Sam68-like mammalian proteins and quaking proteins) in the post-transcriptional regulation of HIV replication. J Biol Chem (2001) 0.86
Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer. J Immunol (2008) 0.86
Comparisons of RNAi approaches for validation of human RNA helicase A as an essential factor in hepatitis C virus replication. J Virol Methods (2008) 0.85
Oncolytic virotherapy as a personalized cancer vaccine. Int J Cancer (2008) 0.83
Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for cancer immunotherapy. Clin Cancer Res (2003) 0.83
Expression, purification, and renaturation of bone morphogenetic protein-2 from Escherichia coli. Protein Expr Purif (2005) 0.83
A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing. Exp Cell Res (2006) 0.83
Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors. Bioorg Med Chem Lett (2011) 0.82
Shifting gene expression profiles during ex vivo culture of renal tumor cells: implications for cancer immunotherapy. Oncol Res (2003) 0.81
Increased pressure stimulates aberrant dendritic cell maturation. Cell Mol Biol Lett (2008) 0.81
Ribozyme technology for cancer gene target identification and validation. Adv Cancer Res (2007) 0.80
PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway. Exp Cell Res (2006) 0.80
Generation of shRNA pool library: a revision of the biological technique from the viewpoint of chemistry. Chembiochem (2008) 0.80
Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase. J Endocrinol (2007) 0.80
Screening of small-molecule compounds as inhibitors of HCV entry. Methods Mol Biol (2009) 0.79
ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther (2012) 0.79
MDDD, a 4,9-diazapyrenium derivative, is selectively toxic to glioma cells by inducing growth arrest at G0/G1 independently of p53. Invest New Drugs (2006) 0.78
Novel technologies for studying virus-host interaction and discovering new drug targets for HCV and HIV. Curr Opin Pharmacol (2002) 0.78
A method for detecting and preventing negative RNA interference in preparation of lentiviral vectors for siRNA delivery. RNA (2009) 0.78
Human immunodeficiency virus type 2 (HIV-2) vector-mediated in vivo gene transfer into adult rabbit retina. Curr Eye Res (2002) 0.78
A novel RNAi library based on partially randomized consensus sequences of nuclear receptors: identifying the receptors involved in amyloid beta degradation. Genomics (2006) 0.78
A 96-well surrogate survival assay coupled with a special short interfering RNA vector for assessing cancer gene targets with enhanced signal/noise ratio and its utility in HTS for cancer therapeutic targets. Assay Drug Dev Technol (2005) 0.78
Integrated approaches to therapeutic target gene discovery. Curr Opin Drug Discov Devel (2002) 0.77
Correction: Inferring Protein Modulation from Gene Expression Data Using Conditional Mutual Information. PLoS One (2016) 0.75
Therapy with ribozyme to the proliferating cell nuclear antigen-ribozyme and 5-fluorouracil of experimental choroidal neovascularization in rats. J Ocul Pharmacol Ther (2006) 0.75
Inverse Genomics as a powerful tool to identify novel targets for the treatment of neurodegenerative diseases. Mech Ageing Dev (2003) 0.75
The development and applications of nonradioactive plate-formatted DNA-binding assay for Ku70/80, a multifunctional DNA-binding protein complex. Assay Drug Dev Technol (2004) 0.75